Metropolitan Life Insurance Co. NY acquired a new stake in Arcus Biosciences Inc (NYSE:RCUS) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 11,459 shares of the company’s stock, valued at approximately $123,000.
Several other institutional investors have also bought and sold shares of the company. Great West Life Assurance Co. Can purchased a new stake in shares of Arcus Biosciences during the fourth quarter worth approximately $51,000. Federated Investors Inc. PA purchased a new stake in shares of Arcus Biosciences during the third quarter worth approximately $55,000. Citigroup Inc. increased its position in shares of Arcus Biosciences by 104.5% during the fourth quarter. Citigroup Inc. now owns 11,395 shares of the company’s stock worth $122,000 after purchasing an additional 5,824 shares in the last quarter. MetLife Investment Advisors LLC purchased a new stake in shares of Arcus Biosciences during the fourth quarter worth approximately $168,000. Finally, Teachers Advisors LLC purchased a new stake in shares of Arcus Biosciences during the third quarter worth approximately $178,000. Institutional investors and hedge funds own 49.11% of the company’s stock.
Shares of NYSE:RCUS opened at $11.23 on Friday. The firm has a market capitalization of $500.13 million and a price-to-earnings ratio of -7.85. Arcus Biosciences Inc has a 52-week low of $8.57 and a 52-week high of $17.50.
Arcus Biosciences (NYSE:RCUS) last issued its earnings results on Tuesday, March 5th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.42) by $0.14. The company had revenue of $1.56 million during the quarter, compared to analysts’ expectations of $1.60 million. Arcus Biosciences had a negative return on equity of 19.83% and a negative net margin of 594.39%. As a group, equities research analysts anticipate that Arcus Biosciences Inc will post -1.67 earnings per share for the current year.
Several analysts recently commented on the company. BTIG Research assumed coverage on Arcus Biosciences in a research report on Monday, March 18th. They set a “buy” rating and a $20.00 price target for the company. Zacks Investment Research upgraded Arcus Biosciences from a “hold” rating to a “buy” rating and set a $13.00 price target for the company in a research report on Thursday, March 7th.
TRADEMARK VIOLATION NOTICE: This story was published by Zolmax and is the sole property of of Zolmax. If you are viewing this story on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this story can be accessed at https://zolmax.com/investing/11459-shares-in-arcus-biosciences-inc-rcus-purchased-by-metropolitan-life-insurance-co-ny/3051940.html.
About Arcus Biosciences
Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing cancer immunotherapies in the United States. It is developing various products for treating solid tumors, including AB928, an adenosine receptor antagonist that is in Phase I clinical trial; AB680, a CD73 inhibitor; AB122, an anti-PD-1 antibody that is Phase I clinical trial; and AB154, an anti-TIGIT antibody.
Read More: Using the New Google Finance Tool
Receive News & Ratings for Arcus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.